Company

Board of Directors

James F. Young, Ph.D.
Director

James F. Young, Ph.D. is president, research and development, at MedImmune, Inc. He has more than 20 years of experience in the fields of molecular genetics, microbiology, immunology and pharmaceutical development. Dr. Young joined MedImmune in 1989 as vice president, research and development, and has since overseen the preclinical development of all products in MedImmune's pipeline, including the company's flagship product, Synagis®, which is the first monoclonal antibody approved for an infectious disease.

From 1983 to 1989, Dr. Young was instrumental in building the department of molecular genetics at Smith Kline & French Laboratories. From 1978 to 1983, he was on the faculty of the department of microbiology at Mount Sinai School of Medicine in New York, NY.

Dr. Young received his doctorate in microbiology and immunology from Baylor College of Medicine in Houston, Texas and Bachelor of Science degrees in biology and general science from Villanova University in Villanova, Pennsylvania.